Insulin Use

Chapter
Part of the Current Clinical Practice book series (CCP)

Abstract

Several clinical trials covering thousands of patient cohorts have clearly demonstrated the correlation between the long-term macrovascular and microvascular complications of diabetes and poorly controlled blood glucose with the subsequent benefits of tighter glycemic control. This data indicates that insulin use (even in the early stages of diabetes) to insure proper glycemic control can be invaluable in reducing mortality and morbidity. In fact, earlier insulin use reduces glucose toxicity, allows endogenous insulin to function more efficiently, and reduces strain on the deteriorating β-cell (1).

Keywords

Sugar Carbohydrate Proline Glucagon Dura 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Bastyr EJ, Stuart CA, Brodows RG, et al. (2000) Therapy focused on lowering postprandial glucose, not fasting glucose, may be superior for lowering HbA1c. IOEZ Study Group. Diabetes Care 23:1236–1241.PubMedCrossRefGoogle Scholar
  2. 2.
    Mayfield J, White RD. (2004) Insulin therapy for type 2 diabetes: rescue, augmentation and replacement of beta-cell function. Am Fam Physician 70:489–500.PubMedGoogle Scholar
  3. 3.
    Burge MR, Schade DS. (1997) Insulins. Endocrinol Metab Clin North Am 26:575–598.PubMedCrossRefGoogle Scholar
  4. 4.
    American Diabetes Association. (2002) Standards of medical care for patients with diabetes mellitus. Diabetes Care 25(Suppl 1):S33–S49.Google Scholar
  5. 5.
    Hermann LS. (2000) Optimizing therapy for insulin-treated type 2 diabetes mellitus. Drugs Aging 17:283–294.PubMedCrossRefGoogle Scholar
  6. 6.
    Mudaliar S, Edelman SV. (2001) Insulin therapy in type 2 diabetes. Endocrinol Metab Clin North Am 30:935–982.PubMedCrossRefGoogle Scholar
  7. 7.
    United Kingdom Prospective Diabetes Study (UKPDS) Group. (1998) A randomized trial of efficacy of early addition of metformin in sulfonylurea-treated type 2 diabetes (UKPDS 28). Diabetes Care 21:87–92.CrossRefGoogle Scholar
  8. 8.
    Turner RC, Holman R, Stratton I. (1999) Correspondence. The United Kingdom Prospective Diabetes Study (UKPDS). Lancet 352:1934.CrossRefGoogle Scholar
  9. 9.
    van den Berghe G, Wouters P, Weekers F, et al. (2001) Intensive insulin therapy in the critically ill patients. N Engl J Med 345:1359–1367.PubMedCrossRefGoogle Scholar
  10. 10.
    Malmberg K. (1997) Prospective randomised study of intensive insulin treatment on long term survival after acute myocardial infarcion in patients with diabetes mellitus. DIGAMI (Diabetes Mellitus, Insulin Glucose Infusion in Acute Myocardial Infarcion) Study Group. BMJ 314:1512–1515.PubMedGoogle Scholar
  11. 11.
    The Diabetes Control and Complications Trial Research Group. (1993) The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 329:977–986.CrossRefGoogle Scholar
  12. 12.
    Ohkubo Y, Kishikawa H, Araki E, et al. (1995) Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study. Diabetes Res Clin Pract 28:103–107.PubMedCrossRefGoogle Scholar
  13. 13.
    de Veciana M, Major CA, Morgan MA, et al. (1995) Postprandial versus preprandial blood glucose monitoring in women with gestational diabetes mellitus requiring insulin therapy. N Engl J Med 333:1237–1241.PubMedCrossRefGoogle Scholar
  14. 14.
    Hirsch IB, McGill JB. (1990) Role of insulin management of surgical patients with diabetes mellitus. Diabetes Care 13:980–991.PubMedCrossRefGoogle Scholar
  15. 15.
    Raskin P, Klaff L, Bergenstal R, Halle JP, Donley D, Mecca T. (2000) A 16-week comparison of the novel insulin analog insulin glargine (HOE 901) and NPH insulin used with insulin lispro in patients with type 1 diabetes. Diabetes Care 23:1666–1671.PubMedCrossRefGoogle Scholar
  16. 16.
    Palumbo PJ. (2004) The case for insulin treatment early in type 2 diabetes. Clev Clin J Med 71:385–386, 391-392, 394.CrossRefGoogle Scholar
  17. 17.
    Holleman F, van den Brand JJ, Hoven RA, et al. (1996) Comparison of LysB28, ProB29-human insulin analog and regular human insulin in the correction of incidental hyperglycemia. Diabetes Care 19:1426–1429.PubMedCrossRefGoogle Scholar
  18. 18.
    Lepore M, Pampanelli S, Fanelli C, et al. (2000) Pharmacokinetics and pharmacodynamics of subcutaneous injection of long-acting human insulin glargine, NPH insulin, and ultralente human insulin and continuous subcutaneous infusion of insulin lispro. Diabetes 49:2142–2148.PubMedCrossRefGoogle Scholar
  19. 19.
    Antsiferov M, Woodworth JR, Mayorov A, et al. (1995) Within patient variability in postprandial glucose excursion with lispro insulin analog compared with regular insulin. Diabetologia 38(Suppl 1):A190.Google Scholar
  20. 20.
    Kelly JL, Hirsch IB, Trence DL. (2002) Rapid decrease in clinically significant hypoglycemia with insulin glargine. Diabetes 51(Suppl 2):A123.Google Scholar
  21. 21.
    Cefalu WT. (2001) Novel routes of insulin delivery for patients with type 1 or type 2 diabetes. Ann Med 33:579–586.PubMedGoogle Scholar
  22. 22.
    Owens DR, Zinman B, Bolli GB. (2001) Insulins today and beyond. Lancet 358:739–746.PubMedCrossRefGoogle Scholar
  23. 23.
    Home PD, Lindholm A, Hylleberg B, Round P. (1998) Improved glycemic control with insulin aspart: a multicenter randomized double-blind crossover trial in type 1 diabetic patients. UK Insulin Aspart Study Group. Diabetes Care 21:1904–1909.PubMedCrossRefGoogle Scholar
  24. 24.
    Kovisto VA, Tuominen JA, Ebeling P. (199) Lispro Mix25 insulin as premeal therapy in type 2 diabetic patients. Diabetes Care 22:459–462.CrossRefGoogle Scholar
  25. 25.
    Rosenfalck AM, Thorsby P, Kjems L, et al. (2000) Improved postprandial glycaemic control with insulin Aspart in type 2 diabetic patients treated with insulin. Acta Diabetol 37:41–46.PubMedCrossRefGoogle Scholar
  26. 26.
    Malone JK, Woodworth JR, Arora V, et al. (2000) Improved postprandial glycemic control with Humalog Mix75/25 after a standard test meal in patients with type 2 diabetes mellitus. Clin Ther 22:222–230.PubMedCrossRefGoogle Scholar
  27. 27.
    Rosskamp RH, Park G. (1999) Long-acting insulin analogs. Diabetes Care 22(Suppl 2):B109–B113.PubMedGoogle Scholar
  28. 28.
    Lepore M, Kurzhals R, Pampanelli S. (1999) Pharacokinetics and dynamics of sup cu injection of the long acting insulin glargine (HOE 1) in TIDM. Diabetes 48(Suppl 1):A97.Google Scholar
  29. 29.
    Yki-Jarvinen H. (2001) Combination therapies with insulin intype 2 diabetes. Diabetes Care 24:758–767.PubMedCrossRefGoogle Scholar
  30. 30.
    Rosenstock J, Riddle MC, Dailey G. (2001) Treatment of target study: feasibility of achieving control with the addition of basal insulin, glargine or NPH in insulin naive patient with type 2 diabetes on oral agents. Diabetes 50(Suppl 2):A520.Google Scholar
  31. 31.
    Rosentock J, Schwartz SL, Clark CM, Park GD, Donely DW, Edward MB. (2001) Basal insulin therapy in type 2 diabetes: 28-week comparision of insulin glargine (HOE 901) and NPH insulin. Diabetes Care 24:631–636.CrossRefGoogle Scholar
  32. 32.
    Yki-Jarvinen H, Ryysy L, Nikkila K, Tulokas T, Vanamo R, Heikkila M. (1999) Comparison of bedtime insulin regimens in patients with type 2 diabetes mellitus. A randomized, controlled trial. Ann Intern Med 130:389–396.PubMedGoogle Scholar
  33. 33.
    Wolffenbuttel BH, Gomis R, Squartrito S, Jones NP, Patwardhan RN. (2000) Addition of low-dose rosiglitazone to sulphonylurea therapy improves glycaemic control in type 2 diabetic patients. Diabet Med 17:40–47.PubMedCrossRefGoogle Scholar
  34. 34.
    Yki-Jarvinen H, Ryysy L, Kauppila M, et al. (1997) Effect of obesity on the response to insulin therapy in noninsulin-dependent diabetes mellitus. J Clin Endocrinol Metab 82:4037–4043.PubMedCrossRefGoogle Scholar
  35. 35.
    Buse J. (2000) Combining insulin and oral agents. Am J Med 108(Suppl 6a):23S–32S.PubMedCrossRefGoogle Scholar
  36. 36.
    Buse JB. (1999) The use of insulin alone and in combination with oral agents in type 2 diabetes. Prim Care 26:931–950.PubMedGoogle Scholar
  37. 37.
    Smith AM, Woods TJ, Williams DJ. (2002) Trandermal basir insulin delivery through microspheres. Program and abstracts of the 62nd scientific sessions of the American Diabetes Association. September 14–18, San Francisco. Abstract 191-OR. Diabetes 51 (Suppl 2).Google Scholar
  38. 38.
    Roberts S. (2003) Amylin analogs. Diabetes self management May/June:49–52.Google Scholar

Copyright information

© Humana Press Inc., Totowa, NJ 2005

Personalised recommendations